{"id":"tazarotene-cream-0-1","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Skin irritation (erythema, burning, stinging)"},{"rate":"15-25","effect":"Peeling and desquamation"},{"rate":"10-20","effect":"Pruritus"},{"rate":"5-10","effect":"Photosensitivity"},{"rate":"5-15","effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a third-generation retinoid, tazarotene selectively activates RXR and RAR nuclear receptors, which modulate transcription of genes involved in cell differentiation, proliferation, and inflammation. This leads to normalization of keratinization, reduced sebum production, and decreased inflammatory mediators in the skin. The drug is particularly effective in psoriasis and acne by promoting skin cell turnover and reducing hyperkeratinization.","oneSentence":"Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:20.855Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Acne vulgaris"},{"name":"Photoaging and photodamaged skin"}]},"trialDetails":[{"nctId":"NCT05573425","phase":"PHASE2, PHASE3","title":"Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2020-08-22","conditions":"Acne Scar","enrollment":202},{"nctId":"NCT00469755","phase":"PHASE4","title":"Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-02","conditions":"Acne Vulgaris","enrollment":302},{"nctId":"NCT05314127","phase":"PHASE2","title":"Efficacy of Tazarotene in Treatment of Verruca Plana","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-04-15","conditions":"Warts Flat","enrollment":80},{"nctId":"NCT01616654","phase":"PHASE2","title":"Dose Range Study of CD5789 in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-06-20","conditions":"Acne Vulgaris","enrollment":304},{"nctId":"NCT03599193","phase":"PHASE2","title":"A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-10-04","conditions":"Acne Vulgaris","enrollment":58},{"nctId":"NCT00489086","phase":"PHASE2","title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2004-07","conditions":"Neoplastic Syndrome","enrollment":36},{"nctId":"NCT03341910","phase":"PHASE2","title":"A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2017-08-21","conditions":"Acne Vulgaris","enrollment":155},{"nctId":"NCT00440024","phase":"NA","title":"The Effect Of A Controlled Daily Skin Care Regimen On Retinoic Acid Tolerance","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2007-02","conditions":"Sun-Damaged Skin, Retinoid Intolerance","enrollment":40},{"nctId":"NCT02886715","phase":"PHASE3","title":"A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Fougera Pharmaceuticals Inc.","startDate":"2016-09-21","conditions":"Acne Vulgaris","enrollment":1110},{"nctId":"NCT03263624","phase":"PHASE4","title":"Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-10-01","conditions":"Nail Psoriasis","enrollment":30},{"nctId":"NCT02411955","phase":"PHASE1","title":"A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2014-06","conditions":"Acne Vulgaris","enrollment":1077},{"nctId":"NCT00713609","phase":"PHASE2","title":"Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-06","conditions":"Acne Vulgaris","enrollment":591},{"nctId":"NCT01016977","phase":"PHASE4","title":"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT02160678","phase":"PHASE3","title":"Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"G & W Laboratories Inc.","startDate":"2014-05","conditions":"Acne Vulgaris","enrollment":1741},{"nctId":"NCT00783965","phase":"PHASE2","title":"Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back","status":"COMPLETED","sponsor":"UCSF Benioff Children's Hospital Oakland","startDate":"2004-07","conditions":"Skin Carcinoma","enrollment":34},{"nctId":"NCT02525822","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris","status":"UNKNOWN","sponsor":"Valeant Pharmaceuticals","startDate":"2015-09","conditions":"Acne Vulgaris","enrollment":210},{"nctId":"NCT02218034","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-08","conditions":"Acne Vulgaris","enrollment":78},{"nctId":"NCT00707174","phase":"NA","title":"Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna","status":"COMPLETED","sponsor":"University of Utah","startDate":"2005-03","conditions":"Cancer, Lentigo Maligna","enrollment":90},{"nctId":"NCT00667589","phase":"PHASE2","title":"Sorafenib-induced Hand- Foot Skin Reaction Treatment","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-06","conditions":"Hand-foot Skin Reaction, Rash","enrollment":6},{"nctId":"NCT00829049","phase":"PHASE4","title":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-10","conditions":"Acne Vulgaris","enrollment":165},{"nctId":"NCT00834210","phase":"PHASE4","title":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":171},{"nctId":"NCT00779896","phase":"PHASE1, PHASE2","title":"Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study","status":"UNKNOWN","sponsor":"McGill University","startDate":"2008-10","conditions":"Cutaneous T-Cell Lymphoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazorac® Cream, 0.1%","Tazorac Cream"],"phase":"marketed","status":"active","brandName":"Tazarotene Cream, 0.1%","genericName":"Tazarotene Cream, 0.1%","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation. Used for Plaque psoriasis, Acne vulgaris, Photoaging and photodamaged skin.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}